UNITED STATES DEPARTMENT OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	Į		
SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO
09/596 101	06/16/00	Patrick de Baetselier	

EXAMINER			
Ford, Vanessa			
ART UNIT 1645	PAPER 12		

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

- 1. This Application contains sequences in the specification which do not comply with 37 CFR 1.821(d) for failing to reference the sequences by the use of sequence identifiers, preceded by SEQ ID NO:" in the text of descriptions.
- 2. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. 1.821 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. 1.136. In no case may an applicant extend the period for response beyond the six months statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.
- 3. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.
- 4. Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989). Should applicant wish to FAX a response, the current Fax number for Group 1600 is (703) 308-4242.

Any inquiry concerning this communication should be directed to Patent Examiner Vanessa Ford, Art Unit 1645 at (703) 308-4735. If attempts to reach the examiner by phone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (703) 308-3909. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice To Comply.

Vanessa Ford

Biotechnology Patent Examiner, Group 1600

Art Unit 1645





THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

De Baetselier et al.

Serial No.: 09/596,101

Filed: 16 June 2000

For: PEPTIDES AND NUCLEIC ACIDS DERIVED FROM EISENIA FOETIDA

AND THE USE THEREOF

Examiner: V. Ford

Group Art Unit: 1645

Attorney Docket No.: 2676-4432US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: <u>EL740516445US</u>

Date of Deposit with USPS: January 23, 2002

Person making Deposit: Orlena Howell

STATEMENT UNDER 37 C.F.R. §§ 1.821 THROUGH 1.825

Commissioner for Patents Washington, D.C. 20231

Sir:

- I, Andrew F. Nilles, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:
- 1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), are included herewith to comply with the requirements of 37 C.F.R. §§ 1.821 and/or 1.825 as requested by the Examiner.
- 2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be the same as the paper copy of the substitute SEQUENCE LISTING.

Serial No.: 09/596,101

3. The SEQUENCE LISTINGS submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,

Andrew F. Nilles

Registration No. 47,825

Attorney for Applicants

TRASKBRITT

P. O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: (801) 532-1922

Date: January 23, 2002

 $N: \label{eq:normalized} N: \label{eq:normal$



Application No. 09/596,101

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING TO THE SECOND SECUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR §1.821 - §1.825 for the following reasons(s):

- [] 1. This application clearly fails to comply with the requirements of 37 CFR §1.821 §1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.
- [] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR §1.821(c).
- [] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR §1.821(e).
- [] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR §1.822 and/or §1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
- [] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR§1.825(d).
- [] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR §1.821(e).
- [X] 7. Other: See the attached letter in regard to compliance with 37 CFR 1.829 (d)

APPLICANT MUST PROVIDE:

- [X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- [X] An initial or substitute paper copy of the "Sequence Listing", as were as an amendment directing its entry into the specification.
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR §1.821(e) or §1.821(f) or §1.821(g) or §1.825(b) or §1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

For Rules Interpretation, call (703) 308-1123 For CRF Submission help, call (703)308-4212 For Patentin Software help, call (703) 557-0400

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE.